Emerging pharmacological treatment options for MAFLD
| Title: | Emerging pharmacological treatment options for MAFLD |
|---|---|
| Authors: | Ángela Rojas, Carmen Lara-Romero, Rocío Muñoz-Hernández, Sheila Gato, Javier Ampuero, Manuel Romero-Gómez |
| Source: | Therapeutic Advances in Endocrinology and Metabolism, Vol 13 (2022) |
| Publisher Information: | SAGE Publishing, 2022. |
| Publication Year: | 2022 |
| Collection: | LCC:Diseases of the endocrine glands. Clinical endocrinology |
| Subject Terms: | Diseases of the endocrine glands. Clinical endocrinology, RC648-665 |
| More Details: | Metabolic dysfunction–associated fatty liver disease (MAFLD) prevalence and incidence is rising globally. It is associated with metabolic comorbidities, obesity, overweight, type 2 diabetes mellitus, and at least two metabolic risk factors, such as hypertension, hypertriglyceridemia, hypercholesterolemia, insulin resistance, and cardiovascular risk, increasing the risk of mortality. The excessive accumulation of fat comprises apoptosis, necrosis, inflammation and ballooning degeneration progressing to fibrosis, cirrhosis, and liver decompensations including hepatocellular carcinoma development. The limitation of approved drugs to prevent MAFLD progression is a paradigm. This review focuses on recent pathways and targets with evidence results in phase II/III clinical trials. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2042-0196 20420188 |
| Relation: | https://doaj.org/toc/2042-0196 |
| DOI: | 10.1177/20420188221142452 |
| Access URL: | https://doaj.org/article/5d35884edc4544099e9179af7c90fdf7 |
| Accession Number: | edsdoj.5d35884edc4544099e9179af7c90fdf7 |
| Database: | Directory of Open Access Journals |
| ISSN: | 20420196 20420188 |
|---|---|
| DOI: | 10.1177/20420188221142452 |
| Published in: | Therapeutic Advances in Endocrinology and Metabolism |
| Language: | English |